Literature DB >> 24147912

Chronic melatonin treatment rescues electrophysiological and neuromorphological deficits in a mouse model of Down syndrome.

Andrea Corrales1, Rebeca Vidal, Susana García, Verónica Vidal, Paula Martínez, Eva García, Jesús Flórez, Emilio J Sanchez-Barceló, Carmen Martínez-Cué, Noemí Rueda.   

Abstract

The Ts65Dn mouse (TS), the most commonly used model of Down syndrome (DS), exhibits several key phenotypic characteristics of this condition. In particular, these animals present hypocellularity in different areas of their CNS due to impaired neurogenesis and have alterations in synaptic plasticity that compromise their cognitive performance. In addition, increases in oxidative stress during adulthood contribute to the age-related progression of cognitive and neuronal deterioration. We have previously demonstrated that chronic melatonin treatment improves learning and memory and reduces cholinergic neurodegeneration in TS mice. However, the molecular and physiological mechanisms that mediate these beneficial cognitive effects are not yet fully understood. In this study, we analyzed the effects of chronic melatonin treatment on different mechanisms that have been proposed to underlie the cognitive impairments observed in TS mice: reduced neurogenesis, altered synaptic plasticity, enhanced synaptic inhibition and oxidative damage. Chronic melatonin treatment rescued both impaired adult neurogenesis and the decreased density of hippocampal granule cells in trisomic mice. In addition, melatonin administration reduced synaptic inhibition in TS mice by increasing the density and/or activity of glutamatergic synapses in the hippocampus. These effects were accompanied by a full recovery of hippocampal LTP in trisomic animals. Finally, melatonin treatment decreased the levels of lipid peroxidation in the hippocampus of TS mice. These results indicate that the cognitive-enhancing effects of melatonin in adult TS mice could be mediated by the normalization of their electrophysiological and neuromorphological abnormalities and suggest that melatonin represents an effective treatment in retarding the progression of DS neuropathology.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Down syndrome; Ts65Dn; glutamatergic synapses; hippocampus; long-term potentiation; melatonin; neurogenesis; oxidative stress

Mesh:

Substances:

Year:  2013        PMID: 24147912     DOI: 10.1111/jpi.12097

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  15 in total

Review 1.  Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology.

Authors:  Md Farhad Hossain; Md Sahab Uddin; G M Sala Uddin; Dewan Md Sumsuzzman; Md Siddiqul Islam; George E Barreto; Bijo Mathew; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2019-06-17       Impact factor: 5.590

2.  Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome.

Authors:  Eduardo B Parisotto; Verónica Vidal; Susana García-Cerro; Sara Lantigua; Danilo Wilhelm Filho; Emilio J Sanchez-Barceló; Carmen Martínez-Cué; Noemí Rueda
Journal:  Neurochem Res       Date:  2016-07-23       Impact factor: 3.996

3.  Neuronal apoptosis can be prevented by the combined therapy with melatonin and hypothermia in a neonatal rat model of hypoxic-ischemic encephalopathy.

Authors:  Alina Mihaela Toader; Oana Hoteiuc; Cristina Bidian; Dan-Daniel Oltean; Flaviu Tabaran; Ovidiu Grad; Simona Clichici; Daniela Rodica Mitrea
Journal:  Med Pharm Rep       Date:  2021-04-29

Review 4.  Timing of therapies for Down syndrome: the sooner, the better.

Authors:  Fiorenza Stagni; Andrea Giacomini; Sandra Guidi; Elisabetta Ciani; Renata Bartesaghi
Journal:  Front Behav Neurosci       Date:  2015-10-06       Impact factor: 3.558

Review 5.  Melatonin and Ischemic Stroke: Mechanistic Roles and Action.

Authors:  Syed Suhail Andrabi; Suhel Parvez; Heena Tabassum
Journal:  Adv Pharmacol Sci       Date:  2015-09-07

Review 6.  Pharmacological approaches to improving cognitive function in Down syndrome: current status and considerations.

Authors:  Katheleen J Gardiner
Journal:  Drug Des Devel Ther       Date:  2014-12-17       Impact factor: 4.162

7.  Developmental effect of light deprivation on synaptic plasticity of rats' hippocampus: implications for melatonin.

Authors:  Sayyed Alireza Talaei; Abolfazl Azami; Mahmoud Salami
Journal:  Iran J Basic Med Sci       Date:  2016-08       Impact factor: 2.699

8.  Aerobic exercise and a BDNF-mimetic therapy rescue learning and memory in a mouse model of Down syndrome.

Authors:  Martina Parrini; Diego Ghezzi; Gabriele Deidda; Lucian Medrihan; Enrico Castroflorio; Micol Alberti; Pietro Baldelli; Laura Cancedda; Andrea Contestabile
Journal:  Sci Rep       Date:  2017-12-04       Impact factor: 4.379

Review 9.  The GABAergic Hypothesis for Cognitive Disabilities in Down Syndrome.

Authors:  Andrea Contestabile; Salvatore Magara; Laura Cancedda
Journal:  Front Cell Neurosci       Date:  2017-03-07       Impact factor: 5.505

Review 10.  Rodent models in Down syndrome research: impact and future opportunities.

Authors:  Yann Herault; Jean M Delabar; Elizabeth M C Fisher; Victor L J Tybulewicz; Eugene Yu; Veronique Brault
Journal:  Dis Model Mech       Date:  2017-10-01       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.